Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)

NCT02151903 is registered in ClinicalTrials.gov with Alopexx Oncology, LLC as lead sponsor.

NCT NCT02151903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02151903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Alopexx Oncology, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
November 4, 2014
Completion date
July 11, 2016
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma